Clinical Research Directory

Inclusion Criteria: * Patient between 18 and 65 years of age * Diagnosis of Multiple Myeloma, requiring a treatment, including high dose Melphalan whith autologous peripheral blood stem cell transplantation * Performance status: \< 2 (Karnofsky \> 70%) * Anticipated survival \> 3 month * Collection of a minimum of 10x106 cells (CD34+)/Kg of autologous G-CSF mobilised peripheral blood stem cells in 2 to 3 pheresis. * Signed and dated informed consent Exclusion Criteria: * Multiple Myeloma not requiring a treatment * Another cancer in the 5 years preceding the diagnosis or evolutive psychiatric affection * Positive serology for HIV, hepatitis C or hepatitis B * Hepato cellular insufficiency * Severe renal insufficiency defined by a creatine clearance \< 30 ml/mn * Women pregnant or nursing, or effective absence of contraception * Antecedent of serious cardiac disease in the last 6 months. * Allergy known to the products derived from Escherichia Coli